Beximco claims to be the first to produce Remdesivir, not Eskayef | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
July 09, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, JULY 09, 2025
Beximco claims to be the first to produce Remdesivir, not Eskayef

Pharma

TBS Report
09 May, 2020, 07:40 pm
Last modified: 09 May, 2020, 10:22 pm

Related News

  • One dies from COVID-19 in 24 hrs
  • Covid-19: Two more deaths, 7 new cases reported in 24hrs
  • Covid-19: One more death, 10 new cases reported in 24hrs
  • Three die from Covid-19 in 24 hrs
  • Five Covid-19 deaths reported in 24 hours, 36 new cases detected

Beximco claims to be the first to produce Remdesivir, not Eskayef

TBS Report
09 May, 2020, 07:40 pm
Last modified: 09 May, 2020, 10:22 pm
File Photo: Vials of investigational coronavirus disease (Covid-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US March 18, 2020. Picture taken March 18, 2020. Gilead Sciences Inc/Handout via Reuters
File Photo: Vials of investigational coronavirus disease (Covid-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US March 18, 2020. Picture taken March 18, 2020. Gilead Sciences Inc/Handout via Reuters

Beximco Pharmaceuticals Ltd claims that it is the first company in Bangladesh, not Eksayef, to produce the potential coronavirus drug Remdesivir.

The pharmaceutical company made the claim in a press note issued on Saturday.

Here is the full press note from Beximco.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"Beximco Pharmaceuticals Ltd has taken notice of the news published in the online version of Daily Star and Daily Prothom Alo on May 8, 2020, (subsequently in their print versions the next day)  titled "Eskayef first to produce Remdesivir in the country" and "করোনার চিকিৎসায় দেশে প্রথম রেমডেসিভির উৎপাদন করল এসকেএফ", wherein it is mentioned that the company initiated distributing preparations from Friday. This was also republished by other news outlets.

We believe the story items were factually incorrect.

We would like to clarify that Beximco Pharma not only was the first company in Bangladesh to produce this drug, but also the only company which has submitted final product samples to the drug regulatory authority, Directorate General of Drug Administration (DGDA), for testing and approval. After producing this generic drug and successfully conducting all necessary tests in house we submitted final product samples to DGDA on 7th May 2020, for testing and approval.

This is a mandatory legal requirement which must be complied with before any company can distribute any drug in Bangladesh or globally. Beximco Pharma refrained from announcing that it has produced the drug because it felt doing so without being validated by the regulatory body would have been irresponsible and unethical and would have misled the public.

We are releasing this press note in greater public interest to clarify the matter and dispel any confusion that may have been caused by the above-mentioned news items."

Corporates / Top News / Covid-19 in Bangladesh

Beximco / Eskayef / COVID-19 / Coronavirus / remdesivir

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Trump's 35% tariff zaps Bangladesh's $8.4 billion export lifeline
    Trump's 35% tariff zaps Bangladesh's $8.4 billion export lifeline
  • Clashes took place between police and protesters in Sylhet on 2 August. Photo: TBS
    BBC verifies Hasina's audio authorising shooting of protesters
  • Illustration: TBS
    Election observers or political props? Reviewing their roles in last 3 polls under AL

MOST VIEWED

  • Illustration: Ashrafun Naher Ananna/TBS Creative
    World’s largest container shipping companies
  • Illustration: Duniya Jahan/TBS Creative
    Inflation drops below 9% after 27 months
  • Representational image
    Dhaka gets relief as Trump pushes tariff deadline to 1 Aug
  • Graph: Reuters
    Trump sends letter to Yunus imposing 35% tariff on Bangladeshi products
  • Illustration: Duniya Jahan/TBS Creative
    Young population believe BNP to get 39% of votes, Jamaat 21%, NCP 16% in national polls: Sanem survey
  • Solar power project in Chattogram. Photo: TBS
    Solar panels to be installed in government buildings, educational institutions, hospitals within six months

Related News

  • One dies from COVID-19 in 24 hrs
  • Covid-19: Two more deaths, 7 new cases reported in 24hrs
  • Covid-19: One more death, 10 new cases reported in 24hrs
  • Three die from Covid-19 in 24 hrs
  • Five Covid-19 deaths reported in 24 hours, 36 new cases detected

Features

Dr Mostafa Abid Khan. Sketch: TBS

Actual impact will depend on how US retailers respond: Mostafa Abid Khan

19h | Economy
Thousands gather to form Bangla Blockade in mass show of support. Photo: TBS

Rebranding rebellion: Why ‘Bangla Blockade’ struck a chord

1d | Panorama
The Mitsubishi Xpander is built with families in mind, ready to handle the daily carpool, grocery runs, weekend getaways, and everything in between. PHOTO: Akif Hamid

Now made-in-Bangladesh: 2025 Mitsubishi Xpander

2d | Wheels
Students of different institutions protest demanding the reinstatement of the 2018 circular cancelling quotas in recruitment in government jobs. Photo: Mehedi Hasan

5 July 2024: Students announce class boycott amid growing protests

4d | Panorama

More Videos from TBS

Will JPA be able to survive in the political arena?

Will JPA be able to survive in the political arena?

8h | TBS Stories
July-August uprising in memory of Chatradal leader

July-August uprising in memory of Chatradal leader

10h | TBS Stories
Is China Ready for Global Leadership?

Is China Ready for Global Leadership?

9h | Others
Solar panels to be installed in government buildings, educational institutions, hospitals within six months

Solar panels to be installed in government buildings, educational institutions, hospitals within six months

11h | TBS Insight
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net